As we reflect on 2024, it’s evident that we have achieved unparalleled success, shaping the future of cardiovascular diagnostics and redefining patient care pathways. From securing pivotal funding and attaining top-tier certifications to expanding our global reach and leading cutting-edge research, this year has been marked by remarkable progress and validation.
We feel truly privileged and deeply grateful for the remarkable growth achieved this year, with the number of registered healthcare professionals nearly doubling to 60,000, up from 32,000 in 2023—an incredible milestone driven entirely by organic acquisition. At the same time, we screened an astounding 1.1 million ECGs, an extraordinary leap from the 150,000 recorded in the previous year.
In addition to these milestones, we initiated more than 40 enterprise pilots across health systems in the US and EU. Below is a comprehensive review of the milestones that have solidified our position as an industry leader in AI-driven cardiovascular care solutions.
Winning Prestigious Industry Awards and Recognition
AHA 2024 Health Tech Competition
Powerful Medical made history as the first company to win both Best Science Startup and Overall Winner awards at the 100th American Heart Association (AHA) Scientific Sessions. This prestigious event brought together close to 20,000 attendees from the global cardiology community, further validating our scientific excellence and impact on healthcare. Explore
Google for Startups: AI for Health
We were honored to join the Google for Startups Growth Academy for our innovative contributions to the AI-health sector. From over 500 applicants across Europe, the Middle East, and Africa, Google chose Powerful Medical as one of the 24 high-potential and high-impact healthcare AI startups to participate in this exclusive program. Read more
Forbes 30 Under 30 Europe
Our co-founders, Martin Herman and Robert Herman, MD, have been recognized as part of the prestigious Forbes 30 Under 30 Europe 2024 list for their work in reshaping cardiovascular care. Selected from thousands of nominations, Martin and Robert’s inclusion in this list reflects their dedication to revolutionizing cardiac diagnostics through artificial intelligence. Read more
Expanding Global Presence Through Leading Industry Events
American College of Cardiology (ACC) 2024
Powerful Medical’s participation at ACC 2024 in Atlanta marked a pivotal milestone in our journey to enter the U.S. healthcare market. We showcased PMcardio to a distinguished audience of cardiologists, healthcare leaders, and potential partners, emphasizing our potential to streamline emergency cardiac care through innovative AI solutions. See more
European Society of Cardiology (ESC) 2024
At ESC 2024 in London, we proudly demonstrated our leadership in AI-driven cardiology by presenting on two prominent stages. A highlight of the event was our Chief Medical Officer, Dr. Robert Herman, delivering an impactful presentation at the Digital Health Stage during the prestigious “Top Publications in the European Heart Journal – Digital Health” session. Learn more
LSI 2024 Emerging MedTech Summit
Powerful Medical made a strong presence at both LSI Emerging MedTech Summit events in 2024—first in California, USA, and later in Lisbon, Portugal. Our CEO, Martin Herman, unveiled the latest advancements of the PMcardio care coordination platform, showcasing its transformative impact. Key results included a 13-hour reduction in door-to-balloon time for heart attack patients and a 67% decrease in false-positive cath-lab activations. Read more
Google Health in the AI Era
Google’s invitation to feature PMcardio at its Health in the AI Era event in Madrid highlighted our technological leadership and vision for the future of AI in medicine. We showcased how PMcardio leverages machine learning to drive life-saving diagnostic precision. Read more
American Heart Association Congress (AHA) 2024
At AHA 2024, we proudly demonstrated our groundbreaking advancements in AI-powered ECG interpretation across multiple sessions and made history as the first to win both the Best Science Startup and Overall Winner awards. Our technology received widespread acclaim for advancing cardiac diagnostics and saving lives through early detection and intervention. Explore
Securing Strategic Funding and Certifications
European Innovation Council (EIC) Funding
In 2024, Powerful Medical secured a €2.5 million grant and a follow-on €5 million investment from the European Innovation Council (EIC). This funding will be used for a multi-center validation across three countries, focusing on leveraging AI to enhance the detection and management of acute coronary syndromes (ACS). Read More
ISO 27001 Certification
The certification marks a pivotal step in safeguarding data security and patient confidentiality. It signifies our robust information security management system, reinforcing trust among healthcare providers and stakeholders globally. More on ISO
SOC 2 Type II and HIPAA Compliance
Highlighting our commitment to rigorous security and privacy protocols, this milestone underscores our dedication to ensuring that all patient data managed through PMcardio meets the highest standards, building confidence among hospitals and healthcare networks. Explore
Advancing STEMI Management Across Healthcare Systems
Heart attacks are a leading cause of mortality, with 10 million annual ER visits in the US for chest pain. PMcardio leverages AI to streamline ECG interpretation and expedite diagnosis, reducing delays and improving outcomes through its innovative ACS pathway.
A flagship initiative of 2024 was the successful launch of PMcardio for Organizations, an enterprise platform tailored to hospital networks and large-scale healthcare providers. Highlights include:
Introducing our Care Coordination platform
Tailored to hospital networks and large-scale healthcare providers, the platform helps streamline acute myocardial infarction detection, enhance ECG interpretation, and optimize cath lab activation processes, while seamlessly integrating into existing workflows.
Moreover, through the Care Coordination platform, we launched desktop and web versions of PMcardio, improving accessibility and driving equity for healthcare providers across diverse settings. Read more
Enhancing Notification Systems
The STEMI Team Notification system built into our care coordination platform now offers manual and automated alerts. Manual options let nurses and ED physicians notify clinicians like interventional cardiologists via customizable SMS, email, or push notifications.
Automated alerts, bypass human intervention for rapid, seamless communication in high-volume ECG settings. Read more
Advancing STEMI Detection
Approximately 30% of STEMI patients experience spontaneous recanalization (TIMI-3 flow) before coronary angiography. To address these complexities, our updated STEMI AI ECG Model is now seamlessly incorporated into an innovative ACS Pathway, able to differentiate recently reopened arteries from active occlusions, guiding optimal intervention timing. Explore
Introducing AI Explainability
For every positive case on our care coordination platform, the explainability feature provides a heat map highlighting the ECG leads and areas of diagnostic importance. This visual tool offers transparency by allowing healthcare professionals to understand how the model arrived at its diagnostic decision. Read more
Expanding AI-Powered ECG to Telemedicine and Primary Care
We extended PMcardio’s reach into telemedicine, pharmacies, and primary care, transforming ECG diagnostics beyond traditional hospital settings. This innovative approach enables early detection of acute cardiac conditions at first-contact points like local pharmacies and primary care offices, bringing advanced care closer to patients. Read more
Driving Scientific Contributions and Validation
AI-ECG TIMI Study
Launched in 2024 and funded by the EIC accelerator grant, this multicenter study evaluates PMcardio’s effectiveness in detecting AMI across diverse populations. The AI-ECG TIMI Study will enroll over 700 patients across three countries and five centers, all presenting with acute coronary syndromes. Read More
PEACE AI Study
This study evaluates the effectiveness of our AI model in detecting occlusive Myocardial Infarction using 12-lead ECGs recorded in patients who have been resuscitated after an out-of-hospital cardiac arrest (OHCA). Read more
Global Validation Pipeline
Our rigorous research spans 40+ clinical sites and over 84,000 chest pain cases, ensuring PMcardio’s models are accurate and applicable across diverse settings. This independent initiative highlights our commitment to generating robust evidence for AI adoption in healthcare. Read more
More Clinical Milestones
- 135,000 Patients Enrolled in External Studies: Including the largest heart attack registry and 6,000 patients enrolled in independent randomized controlled trials (RCTs).
- 12 Publications on Heart Attack Use-Cases: Showcasing our scientific leadership and commitment to evidence-based AI-powered solutions.
- CE–Certification: Achieved this year, with FDA De-Novo clearance expected in 2025.
From Breakthroughs to Momentum
Looking ahead, 2024 stands out as a transformative year for Powerful Medical—defined by remarkable growth, innovation, and measurable progress in advancing cardiovascular care. Building on this solid foundation, we are poised to push boundaries even further in 2025, delivering cutting-edge solutions to health systems worldwide and driving impactful improvements in patient outcomes on a global scale.
